한글목차

본 보고서는 주요 7개국(미국, EU 4개국(독일, 프랑스, 이탈리아, 스페인), 영국, 일본)의 염증성 근염(IM) 치료제 ULTOMIRIS의 동향을 조사했으며, 치료제 개요, 작용기전, 임상개발 데이터, 관련 법규 및 규제, 시판 및 개발중인 약제와의 경쟁 분석, 국가별 시장 규모 추정 및 예측, SWOT 분석, 애널리스트의 견해 등을 정리하여 전해드립니다.

보고서 하이라이트:

• 염증성 근염(IM) 시장 시나리오는 광범위한 연구와 의료비 지출 증가로 인해 향후 몇 년 동안 변화할 것으로 예상됩니다.
• 각 회사는 질병을 치료 및 개선하고, 과제를 평가하고, ULTOMIRIS의 우위에 영향을 미칠 수 있는 기회를 얻기 위해 새로운 접근 방식에 초점을 맞춘 치료제를 개발하고 있습니다.
• 다른 IM 치료제들이 ULTOMIRIS와 치열한 시장 경쟁을 벌일 것으로 예상되며, 조만간 후발주자 신약이 출시되면 시장에 큰 영향을 미칠 것으로 보입니다.
• 법규상의 이정표와 개발 활동에 대한 자세한 설명을 통해 IM에서 ULTOMIRIS의 현재 개발 시나리오를 제공합니다.
• 2027년부터 2032년까지 ULTOMIRIS의 예측 판매 데이터를 상세히 분석하여 IM에서 ULTOMIRIS의 전체 시나리오를 파악하고, 치료제 포트폴리오에 대한 의사결정 과정을 지원합니다.

목차

제1장 보고서 소개

제2장 염증성 근염(IM)의 ULTOMIRIS : 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 프로파일

제3장 경쟁 구도(출시된 치료제)

제4장 경쟁 구도(후기 단계 신흥 치료제)

제5장 ULTOMIRIS : 시장 평가

• IM의 ULTOMIRIS : 시장 전망
• 주요 7개국 분석
  • IM 치료제 ULTOMIRIS 시장 규모
• 국가별 시장 분석
  • 시장 규모 : 미국
  • 시장 규모 : 독일
  • 시장 규모 : 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 보고서 구입 옵션

영문목차

"ULTOMIRIS Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about ULTOMIRIS for Inflammatory Myositis (IM) in the seven major markets. A detailed picture of the ULTOMIRIS for IM in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the ULTOMIRIS for IM. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ULTOMIRIS market forecast analysis for IM in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in IM.

Drug Summary:

ULTOMIRIS (ravulizumab), the first and only long-acting C5 complement inhibitor, offers immediate, complete, and sustained complement inhibition. The medication works by inhibiting the C5 protein in the terminal complement cascade, a part of the body's immune system. When activated uncontrolled, the complement cascade over-responds, leading the body to attack its healthy cells. ULTOMIRIS is administered intravenously every 8 weeks in adult patients, following a loading dose.

The company is actively recruiting for its registration Phase II/III study, which started in December 2021 and was expected to be completed by May 2024.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the ULTOMIRIS description, mechanism of action, dosage and administration, research and development activities in Inflammatory Myositis (IM).
• Elaborated details on ULTOMIRIS regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ULTOMIRIS research and development activities in IM across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around ULTOMIRIS.
• The report contains forecasted sales of ULTOMIRIS for IM till 2032.
• Comprehensive coverage of the late-stage emerging therapies for IM.
• The report also features the SWOT analysis with analyst views for ULTOMIRIS in IM.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ULTOMIRIS Analytical Perspective by DelveInsight

• In-depth ULTOMIRIS Market Assessment

This report provides a detailed market assessment of ULTOMIRIS for Inflammatory Myositis (IM) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2025 to 2032.

• ULTOMIRIS Clinical Assessment

The report provides the clinical trials information of ULTOMIRIS for Inflammatory Myositis (IM) covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Inflammatory Myositis (IM) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ULTOMIRIS dominance.
• Other emerging products for IM are expected to give tough market competition to ULTOMIRIS and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ULTOMIRIS in IM.
• Our in-depth analysis of the forecasted sales data of ULTOMIRIS from 2025 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ULTOMIRIS in IM.

Key Questions:

• What is the product type, route of administration and mechanism of action of ULTOMIRIS?
• What is the clinical trial status of the study related to ULTOMIRIS in Inflammatory Myositis (IM) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ULTOMIRIS development?
• What are the key designations that have been granted to ULTOMIRIS for IM?
• What is the forecasted market scenario of ULTOMIRIS for IM?
• What are the forecasted sales of ULTOMIRIS in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to ULTOMIRIS for IM?
• Which are the late-stage emerging therapies under development for the treatment of IM?

Table of Contents

1. Report Introduction

2. ULTOMIRIS Overview in Inflammatory Myositis (IM)

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. ULTOMIRIS Market Assessment

• 5.1. Market Outlook of ULTOMIRIS in Inflammatory Myositis (IM)
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of ULTOMIRIS in the 7MM for Inflammatory Myositis (IM)
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of ULTOMIRIS in the United States for Inflammatory Myositis (IM)
  • 5.3.2. Market Size of ULTOMIRIS in Germany for Inflammatory Myositis (IM)
  • 5.3.3. Market Size of ULTOMIRIS in France for Inflammatory Myositis (IM)
  • 5.3.4. Market Size of ULTOMIRIS in Italy for Inflammatory Myositis (IM)
  • 5.3.5. Market Size of ULTOMIRIS in Spain for Inflammatory Myositis (IM)
  • 5.3.6. Market Size of ULTOMIRIS in the United Kingdom for Inflammatory Myositis (IM)
  • 5.3.7. Market Size of ULTOMIRIS in Japan for Inflammatory Myositis (IM)

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options